skip navigation links
National Cancer Institute
EVS Logo NCI Term Browser Enterprise Vocabulary Services
Terminologies Value Sets Mappings
Version: 17.06d (Release date: 2017-06-26)
SearchBox Top
SearchBox Bottom
Daratumumab (Code C74007)

Terms & Properties Synonym Details Relationships Mapping View All  
Terms & Properties

Preferred Name: Daratumumab

Definition: A fully human monoclonal antibody directed against the cell surface glycoprotein CD-38 with potential antineoplastic activity. The binding of anti-CD38 monoclonal antibody to natural killer (NK) cells mimics the normal CD38-CD31 interaction on the NK cell surface. CD38 is also present on multiple myeloma (MM) cells and plasma leukemia cells; this agent may preferentially bind these cells, triggering antitumoral antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC). CD38, a cell surface glycoprotein, is present on various immune cells and has been shown to regulate the cytotoxic response of activated NK cells.

Display Name: Daratumumab

Label: Daratumumab

NCI Thesaurus Code: C74007 (Search for linked caDSR metadata)  (search value sets)

NCI Metathesaurus Link: C2346801  (see NCI Metathesaurus info)

Synonyms & Abbreviations: (see Synonym Details)
Anti-CD38 Monoclonal Antibody

External Source Codes: 
CAS Registry Number 945721-28-8 (see NLM ChemIDplus info)
PDQ Closed Trial Search ID 583564
PDQ Open Trial Search ID 583564 (check for NCI PDQ open clinical trial info)
UMLS CUI C2346801

Other Properties:
     Name Value (qualifiers indented underneath)
code C74007
Contributing_Source CTRP
Contributing_Source FDA
Legacy_Concept_Name Anti-CD38_Monoclonal_Antibody
Semantic_Type Pharmacologic Substance

Additional Concept Data: 
Defined Fully by Roles: No  


Mainbox Bottom